CardioWest(TM) Temporary Total Artificial Heart to Expand from 9 to 28 Transplant Hospitals Worldwide in 2006.TUCSON, Ariz. -- Rodger Ford, CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. of SynCardia Systems Inc., told stockholders at the Tucson-based company's annual meeting that the number of hospitals certified to use the company's CardioWest Total Artificial Heart-temporary (TAH-t) is expected to grow from nine transplant hospitals worldwide in 2005, to 28 in 2006. The TAH-t is the only FDA-approved device capable of providing circulatory restoration in morbidly ill patients with irreversible bi-ventricular failure, bridging them to transplantation when a donor human heart becomes available. According to according to prep. 1. As stated or indicated by; on the authority of: according to historians. 2. In keeping with: according to instructions. 3. Ford, SynCardia will add two hospitals a month to its implant program, making the TAH-t life-saving technology available to more physicians and patients. He said that when SynCardia reaches its 2006 goal, it will have been converted from a scientific venture into a profitable business. SynCardia currently services two transplant hospitals in the United States Lists of hospitals for each U.S. state:
In addition to the FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. , TAH-t has also been approved by Health Canada and has the CE mark for use in Europe and in other countries. The company received the Frost & Sullivan 2005 Entrepreneurial Company of the Year award in the cardiovascular device market. The TAH-t was named the No. 1 advancement in Cardiovascular Medicine by the American Heart Association American Heart Association (AHA), n.pr a national voluntary health agency that has the goal of increasing public and medical awareness of cardiovascular diseases and stroke, and thereby reducing the number of associated deaths and disabilities. in 2004. SynCardia Systems Inc. was formed in 2001 by Marvin J. Slepian, M.D., chairman of the board and chief scientific officer; and Richard G. Smith, MSEE MSEE Master of Science in Electrical Engineering MSEE Mean Square Estimation Error MSEE Major Source Enforcement Effort MSEE Materials Science and Electrical Engineering (Purdue University building) , CCE CCE Cornell Cooperative Extension CCE Corporate and Continuing Education CCE Coca-Cola Enterprises Inc. CCE Commission de Coopération Environnementale CCE Centre for Continuing Education CCE College of Continuing Education CCE Certified Computer Examiner , chief technical officer. Noted Cardiac Transplant and TAH-t surgeon, Jack Copeland, M.D. is on the board of directors of SynCardia Systems Inc. Slepian and Copeland also serve as instructors for the three-part training program required of hospitals adding TAH-t technology. Pictures and captions are available and include:
Picture: Marvin J. Slepian, M.D., Chairman of the Board and Chief
Scientific Officer
Picture: Rodger Ford, CEO
Picture: Richard G. Smith, MSEE, CCE and Chief Technical Officer
Picture: Jack Copeland, M.D., SynCardia Board of Directors
Picture: CardioWest(TM) TAH-t
CardioWest(TM) temporary Total Artificial Heart (TAH-t)
|
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion